Impact of metabolic complications on antiretroviral treatment adherence: Clinical and public health implications
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Antiretroviral therapy (ART) is an effective strategy for preventing disease progression of HIV infection, particularly when patients adhere closely to the treatment regimen. However, ART medications can cause side effects, including metabolic complications that can impact patients’ adherence levels. Selected chronic complications associated with ART include lipodystrophy, hyperlipidemia, insulin resistance and diabetes, peripheral neuropathy, and bone disorders such as osteopenia/osteoporosis. In this article, we review the effects of these metabolic complications on ART adherence and approaches to prevent or reverse them
- O’Brien ME, Clark RA, Besch CL, et al.: Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003, 34:407–414. CrossRef
- Wohl DA, McComsey G, Tebas P, et al.: Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006, 43:645–653. CrossRef
- Lenert LA, Feddersen M, Sturley A, Lee D: Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am J Med 2002, 113:229–232. CrossRef
- Vranceanu AM, Safren SA, Lu M, et al.: The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care STDS 2008, 22:313–321. CrossRef
- Ammassari A, Cozzi-Lepri A, Trotta MP, et al.: ICoNA Cohort: Treatment complexity and risk of virological rebound in persons receiving cART [abstract 522]. Programs and Abstracts for the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.
- Willig JH, Abroms S, Westfall AO, et al.: Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008, 22:1951–1960. CrossRef
- Mills EJ, Nachega JB, Bangsberg DR, et al.: Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006, 3:e438. CrossRef
- d’Arminio Monforte A, Lepri AC, Rezza G, et al.: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 2000, 14:499–507. CrossRef
- Amoroso A, Sheneberger R, Edozien A, et al.: Antiretroviral-associated drug toxicities leading to a switch in medication: experience in Uganda, Kenya, and Zambia [poster 587]. In Programs and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007. Available at http://www.retroconference.org/2007/PDFs/789.pdf. Accessed April 10, 2009.
- Mills EJ, Nachega JB: A wake up call for global access to salvage HIV regimens. Lancet 2007, 370:1885–1887. CrossRef
- Heath KV, Montaner JS, Bondy G, et al.: Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. Curr Drug Targets 2003, 4:13–22. CrossRef
- Ammassari A, Murri R, Pezzotti P, et al.; AdICONA Study Group: Self-reported symptoms and medications side effects influence adherence to HAART in persons with HIV infection. J Acquir Immune Defic Syndr 2001, 28:445–449.
- Duran S, Spire B, Raffi F, et al.: Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001, 2:38–45. CrossRef
- Dube MP, Parker RA, Tebas P, et al.: Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005, 19:1807–1818.
- Kim TW, Palepu A, Cheng DM, et al.: Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems. AIDS Care 2007, 19:1039–1047. CrossRef
- Guaraldi G, Murri R, Orlando G, et al.: Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials 2003, 4:99–106. CrossRef
- Blanch J, Rousaud A, Martínez E, et al.: Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004, 38:1464–1470. CrossRef
- Power R, Tate HL, McGill SM, Taylor C: A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 2003, 79:137–141. CrossRef
- Lichtenstein KA, Ward DJ, Morman AC, et al.: Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001, 15:1389–1398. CrossRef
- Parker RA, Komarow L, Grinspoon KK, et al.: Baseline and early on-treatment predictors of lipoatrophy at week 64 in a randomized trial of initial antiretroviral therapy: a secondary analysis of A5005s, a substudy of ACTG 384. Seventh International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, in Dublin, Ireland. Antivir Ther 2005, 10(Supp 3):15–16.
- Mallal SA, John M, Moore CB, et al.: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309–1316. CrossRef
- Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191–201. CrossRef
- Brinkman K, Smeitink JA, Romijn JA, et al.: Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy lipodystrophy. Lancet 1999, 354:1112–1115. CrossRef
- Lee H, Hanes J, Johnson KA: Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003, 42:14711–14719. CrossRef
- Sax PE, Kumar P: Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 2004, 37:1111–1124. CrossRef
- Milinkovic A, Martinez E, López S, et al.: The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007, 12:407–415.
- Moyle GJ, Sabin CA, Cartledge J, et al.: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006, 20:2043–2050. CrossRef
- Podzamczer D, Ferrer E, Sanchez P, et al.; ABCDE (Abacavir vs. d4T [Stavudine] Plus Efavirenz) Study Team: Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007, 44:139–147. CrossRef
- Gallant JE, DeJesus E, Arribas JR, et al.: Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251–260. CrossRef
- Moyle G, Fisher M; SWEET study group: A randomized comparison of continued zidovudine plus lamivudine BID (AZT/3TC) vs switching to tenofovir DF plus emtricitabine (FTC/TDF) each plus efavirenz (EFV) in stable HIV infected persons: 48 week study—results of a planned 24 week analysis [abstract WEPEB028]. In Program and Abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; July 22–25, 2007.
- Cooper V, Horne R, Moyle G, et al.: Simplification with Easier Emtricitabine and Tenofovir (SWEET): results of a 48 week analysis of patients’ perceptions of treatment and adherence [poster TUPE0065]. Programs and Abstracts of the XVII International AIDS Conference. Mexico City, Mexico; August 3–8, 2008.
- Tebas P: Metabolic toxicities and impact on adherence. Second Botswana International HIV/AIDS Conference. Gaborone, Botswana; September 17–20, 2008. Available at http://www.botshiv.org.bw/view_details.php?name=SAHIV%20Conference%202008. Accessed April 11, 2009.
- Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48–62. CrossRef
- van Leth F, Phanuphak P, Stroes E, et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. Plos Med 2004, 1:e19. CrossRef
- Vergis EN, Paterson DL, Wagener MM, et al.: Dyslipidaemia in HIV-infected patient: association with adherence to highly active antiretroviral therapy. Int J STD AIDS 2001, 12:463–468. CrossRef
- Calza L, Manfredi R, Colangeli V, et al.: Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005, 19:1051–1058. CrossRef
- Bury JE, Stroup JS, Stephens JR, Baker DL: Achieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitus. Proc (Bayl Univ Med Cent) 2007, 20:118–123.
- Siris ES, Selby PL, Saag KG, et al.: Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009, 122(Suppl):S3–S13. CrossRef
- Tebas P, Powderly WG, Claxton S, et al.: Accelerated bone mineral loss in HIV infected patients receiving potent antiretroviral therapy. AIDS 2000, 14:F63–F67. CrossRef
- Amorosa V, Tebas P: Bone disease and HIV infection. Clin Infect Dis 2006, 42:108–114. CrossRef
- Arnsten JH, Freeman R, Howard AA, et al.: Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007, 21:617–623. CrossRef
- Brown TT, Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165–2174. CrossRef
- Collin F, Duvan X, Le Moing V, et al.: Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009 Mar 19 (Epub ahead of print).
- Boonen S, Singer AJ: Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture I. Curr Med Res Opin 2008, 24:1781–1788. CrossRef
- Martin AR, Sornay-Rendu E, Chandler JM, et al.: The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone 2002, 31:32–36. CrossRef
- Mondy K, Powderly W, Claxton SA, et al.: Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005, 38:426–431. CrossRef
- Clay PG, Voss LE, Williams C, Daume EC: Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacother 2008, 42:670–679. CrossRef
- Sacktor N, Nakasujja N, Skolasky RL, et al.: Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009, 72:165–170. CrossRef
- Sithinamsuwan P, Punthanamongkol S, Valcour V, et al.: Frequency and characteristics of HIV-associated sensory neuropathy among HIV patients in Bangkok, Thailand. J Acquir Immune Defic Syndr 2008, 49:456–458. CrossRef
- Collazos J: Sexual dysfunction in the highly active antiretroviral therapy era. AIDS Rev 2007, 9:237–245.
- Miguez-Burbano MJ, Espinoza L, Lewis JE: HIV treatment adherence and sexual functioning. AIDS Behav 2008, 12:78–85. CrossRef
- Trotta MP, Ammassari A, Murri R, et al.: Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals. AIDS Patient Care STDS 2008, 22:291–299. CrossRef
- Lallemand F, Salhi Y, Linard F, et al.: Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr 2002, 30:187–190.
- Trotta MP, Ammassari A, Murri R, et al.: Sexual dysfunction in HIV infection. Lancet 2007, 369:905–906. CrossRef
- Diamond C, Richardson JL, Milam J, et al.; California Collaborative Trials Group: Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. J Acquir Immune Defic Syndr 2005, 39:211–218.
- Subbaraman R, Chaguturu SK, Mayer KH, et al.: Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007, 45:1093–1101. CrossRef
- Robison LS, Westfall AO, Mugavero MJ, et al.: Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 2008, 24:1347–1355. CrossRef
- Impact of metabolic complications on antiretroviral treatment adherence: Clinical and public health implications
Current HIV/AIDS Reports
Volume 6, Issue 3 , pp 121-129
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links